Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAVITRI: Osavampator (NBI-1065845) in Major Depressive Disorder
NCT05203341Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2022
- Primary completion
- Jan 2024
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of osavampator in major depressive disorder (MDD), sponsored by Neurocrine Biosciences. Started Feb 2022; status: completed.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05203341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203341.